Opportunity ID: |
331331 |
Opportunity Number: |
NOT-AA-21-003 |
Opportunity Title: |
Notice of Intent to Publish a Funding Opportunity Announcement for SARS-CoV-2, COVID-19 and Consequences of Alcohol Use (R21 Clinical Trials Not Allowed) |
Opportunity Category: |
Discretionary |
Opportunity Category Explanation: |
|
Funding Instrument Type: |
Grant |
Category of Funding Activity: |
Health |
Category Explanation: |
|
CFDA Number(s): |
93.273 |
Eligible Applicants: |
State governments County governments Independent school districts Public and State controlled institutions of higher education Native American tribal governments (Federally recognized) Public housing authorities/Indian housing authorities Native American tribal organizations (other than Federally recognized tribal governments) Nonprofits having a 501(c)(3) status with the IRS, other than institutions of higher education Private institutions of higher education For profit organizations other than small businesses Small businesses Others (see text field entitled “Additional Information on Eligibility” for clarification) |
Additional Information on Eligibility: |
|
Agency Code: |
HHS-NIH11 |
Agency Name: |
Department of Health and Human Services National Institutes of Health |
Posted Date: |
Feb 04, 2021 |
Last Updated Date: |
Feb 04, 2021 |
Estimated Synopsis Post Date: |
Feb 15, 2021 |
Fiscal Year: |
2021 |
Award Ceiling: |
$150,000 |
Award Floor: |
|
Estimated Total Program Funding: |
$1,000,000 |
Expected Number of Awards: |
3 |
Description: |
The National Institute on Alcohol Abuse and Alcoholism intends to promote a new initiative by publishing a Funding Opportunity Announcement (FOA) to solicit applications for addressing urgent, time-sensitive research questions on the relationships between alcohol consumption/misuse and COVID-19 related outcomes and consequences. This Notice is being provided to allow potential applicants sufficient time to develop meaningful collaborations and responsive projects. The FOA is expected to be published in late winter 2021 with an expected application due date in spring 2021. This FOA will utilize the R21 activity code and clinical trials will not be allowed. |
Version: |
1 |